Beck, L. A., Thaçi, D., Deleuran, M., Blauvelt, A., Bissonnette, R., de Bruin-Weller, M., . . . Shumel, B. (2020). Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol.

Beck, Lisa A., et al. "Dupilumab Provides Favorable Safety and Sustained Efficacy for Up to 3 Years in an Open-Label Study of Adults With Moderate-to-Severe Atopic Dermatitis." Am J Clin Dermatol 2020.

Beck, Lisa A., et al. "Dupilumab Provides Favorable Safety and Sustained Efficacy for Up to 3 Years in an Open-Label Study of Adults With Moderate-to-Severe Atopic Dermatitis." Am J Clin Dermatol 2020.